Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Healthcare Advertising Agencies

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Post by Barethoughtson Dec 29, 2017 12:22pm

71 Views

Post# 27246005

Tenant-Grower Provides Company with Crop Test

October 18/2017 (News Release on www.sedar.com)
“The delay caused by this changeover is a setback for our tenant-grower over which they have no control. Both the Company and our client are anxiously awaiting these results so that the product can be prepared for market. Until then, we remain optimistic that the sale of the product will generate the required revenues that will move the Company and its tenant-grower on to the next crop and future growth.”….all kinds of excuses given prior to this one!!

Now NF issuing securities 2 move the company forward with no explanations as to what happened to the crop.

Bullboard Posts

Golden Minerals closes Yoquivo gold-silver project sale